Trial Profile
Mirabegron and Urinary Urgency Incontinence: The Clinical Response and the Female Urinary Microbiome
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jun 2022
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 01 May 2022 Results of an analysis assessed the association between symptoms improvement and urobiome changes published in the International Urogynecology Journal
- 30 Oct 2020 Status changed from recruiting to completed.
- 22 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2020.